Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD

1.630

-0.090 (-5.23%)

At close: Apr 23, 2024, 4:00 PM

1.690

+0.060 (3.68%)

Pre-market: Apr 24, 2024, 8:05 AM EDT

Immuneering Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-53.47	-50.51	-33.54	-17.04	-7.71
Depreciation & Amortization	0.76	0.8	0.16	0.08	0.02
Share-Based Compensation	5.73	4.06	1.8	1.09	0.6
Other Operating Activities	-1.99	1.55	0.72	1.25	2.65
Operating Cash Flow	-48.97	-44.1	-30.85	-14.62	-4.44
Capital Expenditures	-0.34	-0.74	-0.06	-0.05	-0.02
Acquisitions	0	0	0.07	0	0
Change in Investments	7.64	42.57	-75.63	0	0
Investing Cash Flow	7.3	41.83	-75.62	-0.05	-0.02
Share Issuance / Repurchase	28.64	0.3	119.48	0	0
Debt Issued / Paid	0	0	0	0	3.77
Other Financing Activities	-0.2	-0.28	24.79	37.98	13.4
Financing Cash Flow	28.44	0.02	144.26	37.98	17.17
Net Cash Flow	-13.23	-2.25	37.8	23.31	12.71
Free Cash Flow	-49.31	-44.84	-30.91	-14.67	-4.46
Free Cash Flow Margin	-	-14148.44%	-1486.17%	-634.83%	-232.48%
Free Cash Flow Per Share	-1.74	-1.70	-2.27	-2.96	-1.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).